HARVARD BIOSCIENCE INC (HBIO): Results of Operations and Financial Condition
HARVARD BIOSCIENCE INC (HBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2026 Financial Results · Second Quarter 2026 Revenue Growth of 11% Year Over Year to $22.7 Million · Raises Full Year 2026 Revenue Guidance to 3%-5% Year Over Year Growth HOLLISTON, Mass.,
How this was made
The 30-second read
Why it matters
The key tradable items are the raised full-year revenue guidance and the updated adjusted gross margin and adjusted EBITDA growth ranges, plus Q3 revenue and profitability guidance.
Market read
Investors get a fresh datapoint set: Q2 revenue and margin performance, Q3 outlook ranges, and a raised full-year revenue and adjusted EBITDA growth outlook.
What to watch
Cash from operations was negative ($0.3M used in) over the first six months, so investors may scrutinize working-capital dynamics alongside adjusted metrics.
Background
This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 covering Harvard Bioscience’s Q2 2026 financial results and updated Q3 and full-year 2026 guidance.
Ticker impact
Harvard Bioscience reported Q2 2026 revenue of $22.7M (+11% YoY) and raised full-year 2026 revenue guidance to 3%-5% growth.
Near-term bias upward if investors focus on the raised full-year revenue and EBITDA growth ranges; margin/mix concerns could cap upside.
The filing discloses both Q2 results and updated full-year targets (revenue growth 3%-5%, adjusted gross margin 57%-59%, adjusted EBITDA growth 6%-10%), which are actionable for positioning into subsequent quarters.
Market effects
Signals demand strength and commercialization traction in Harvard Bioscience’s CMT and preclinical platform, potentially supportive for small-cap life science tools sentiment.
China mix noted as a driver of slight gross margin impact, relevant for investors tracking regional demand sensitivity.
Limited direct global spillover beyond small-cap biotech tools, but guidance updates can affect peer read-through on lab-tech spending.
Counterpoint
Raised revenue guidance may be offset by lower-margin CMT volume and geographic mix, limiting margin expansion despite EBITDA growth.
Key entities
- companyHarvard Bioscience, Inc.
Nasdaq-listed company reporting Q2 2026 results and raising full-year 2026 guidance.
- executiveJohn Duke
President and CEO quoted on demand strength and CMT outperformance.
